GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ContraFect Corp (OTCPK:CFRXQ) » Definitions » ROC (Joel Greenblatt) %

ContraFect (ContraFect) ROC (Joel Greenblatt) % : -1,040.64% (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is ContraFect ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. ContraFect's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -1,040.64%.

The historical rank and industry rank for ContraFect's ROC (Joel Greenblatt) % or its related term are showing as below:

CFRXQ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2868.57   Med: -1340.02   Max: -638.62
Current: -1108.61

During the past 11 years, ContraFect's highest ROC (Joel Greenblatt) % was -638.62%. The lowest was -2868.57%. And the median was -1340.02%.

CFRXQ's ROC (Joel Greenblatt) % is ranked worse than
68.5% of 1470 companies
in the Biotechnology industry
Industry Median: -339.53 vs CFRXQ: -1108.61

ContraFect's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 9.30% per year.


ContraFect ROC (Joel Greenblatt) % Historical Data

The historical data trend for ContraFect's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ContraFect ROC (Joel Greenblatt) % Chart

ContraFect Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,868.57 -1,067.66 -870.67 -1,349.27 -1,849.15

ContraFect Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,937.16 -933.54 -1,261.60 -1,185.43 -1,040.64

Competitive Comparison of ContraFect's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, ContraFect's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ContraFect's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ContraFect's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where ContraFect's ROC (Joel Greenblatt) % falls into.



ContraFect ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.092) - (14.04 + 0 + 1.756)
=-13.704

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.107) - (10.06 + 0 + 1.583)
=-10.536

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of ContraFect for the quarter that ended in Sep. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Sep. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-26.708/( ( (2.633 + max(-13.704, 0)) + (2.5 + max(-10.536, 0)) )/ 2 )
=-26.708/( ( 2.633 + 2.5 )/ 2 )
=-26.708/2.5665
=-1,040.64 %

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ContraFect  (OTCPK:CFRXQ) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


ContraFect ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of ContraFect's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


ContraFect (ContraFect) Business Description

Traded in Other Exchanges
N/A
Address
28 Wells Avenue, 3rd Floor, Yonkers, NY, USA, 10701
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
Executives
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Lishan Aklog director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Michael Messinger officer: VP Finance 238 PENNINGTON HARBURTON ROAD, PENNINGTON NJ 08534
Cary Sucoff director 1612 EAST CAPE CORAL PKWY, C/O LEGACY EDUCATION ALLIANCE, INC., CAPE CORAL FL 33904
David N. Low director EMBARCADERO FOUR, SUITE 650, SAN FRANCISCO CA 94111
Sol J Barer director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Lisa Ricciardi director C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Joshua B Muntner officer: SVP Business Development 30 FIFTH AVENUE, 12F, NEW YORK NY 10011
Shanghai Fosun Pharmaceutical (group) Co., Ltd. 10 percent owner BUILDING A, NO. 1289 YISHAN ROAD, SHANGHAI F4 200233
Fosun Industrial Co., Ltd 10 percent owner FLAT/ROOM 808, ICBC TOWER, 3 GARDEN ROAD, HONG KONG F4 00000
Cara M Cassino officer: Chief Medical Officer 757 STONY POINT ROAD, BENSON VT 05743
Natalie Bogdanos officer: General Counsel 207-23 DARREN DRIVE, BAYSIDE NY 11360
Roger Pomerantz director 711 HARVEST HILL ROAD, CHALFONT PA 18914
Michael J. Otto director 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421

ContraFect (ContraFect) Headlines

From GuruFocus